期刊文献+

冠心病病人脂蛋白相关磷脂酶A2与冠状动脉狭窄严重程度及预后的关系

Relationship between Lp-PLA2 and the Severity of Coronary Stenosis and Prognosis in Patients with Coronary Heart Disease
在线阅读 下载PDF
导出
摘要 目的:探讨脂蛋白相关磷脂酶A2(Lp-PLA2)与冠心病病人冠状动脉狭窄严重程度及预后的关系。方法:选取2020年11月—2022年3月在新乡医学院第一附属医院心内科行冠状动脉造影及Lp-PLA2检测的病人266例,根据冠状动脉造影结果分为冠心病组(冠状动脉狭窄≥50%,199例)、对照组(冠状动脉狭窄<50%,67例);依据冠状动脉病变支数将冠心病组分为单支病变组(48例)、双支病变组(50例)、三支病变组(101例);根据Lp-PLA2水平将冠心病组分为Lp-PLA2升高组(Lp-PLA2≥200 ng/mL,80例)、Lp-PLA2正常组(Lp-PLA2<200 ng/mL,119例),并对两组病人进行性别分层。比较冠心病组与对照组一般资料,比较冠心病组不同病变支数病人Gensini评分及Lp-PLA2水平。对冠心病病人进行随访并记录不良事件发生情况。应用多因素COX回归风险模型分析Lp-PLA2水平与预后的关系。采用Kaplan-Meier法绘制生存曲线并行Log-rank检验。结果:与对照组比较,冠心病组Lp-PLA2水平明显升高(P<0.05)。与单支病变组、双支病变组比较,三支病变组Lp-PLA2水平、Gensini评分均明显升高(P<0.05)。Spearman相关性分析显示,冠心病组病人Lp-PLA2水平与冠状动脉狭窄程度呈正相关(r=0.423,P<0.001)。Lp-PLA2升高的冠心病病人不良事件发生率为33.8%,Lp-PLA2正常病人不良事件发生率为20.2%。多因素COX回归分析显示,Lp-PLA2水平升高与冠心病病人不良事件风险增加相关[HR=2.730,95%CI(1.501,4.966),P=0.001]。Kaplan-Meier法生存分析显示,Lp-PLA2升高组随访期间不良事件发生率高于Lp-PLA2正常组(P<0.05)。性别分组后仅男性病人Lp-PLA2升高组随访期间不良事件发生率高于Lp-PLA2正常组(P<0.05),女性病人中两组随访期间不良事件发生率比较差异无统计学意义(P>0.05)。结论:冠心病病人Lp-PLA2水平明显高于非冠心病病人,且与冠状动脉狭窄程度呈正相关,可评估冠状动脉病变严重程度。高Lp-PLA2水平可能是冠心病病人不良预后的独立危险因素,尤其是男性冠心病病人。
作者 吕冬晨 黄笑 杨倩 袁宇 LYU Dongchen;HUANG Xiao;YANG Qian;YUAN Yu(The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453300,Henan,China)
出处 《中西医结合心脑血管病杂志》 2025年第3期413-417,共5页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 冠心病 脂蛋白相关磷脂酶A2 冠状动脉狭窄 预后 GENSINI评分 coronary heart disease lipoprotein-associated phospholipase A2 coronary stenosis prognosis Gensini score
  • 相关文献

参考文献8

二级参考文献79

  • 1Maiolino G, Pedon L, Cesari M, et al. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PloS One, 2012, 7: e48171.
  • 2Hassan M. STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Glob Carrtiol Sci Pracl, 2015, 2015: 6.
  • 3Burke J, Dennis E. Phospholipase A2 biochemistly. Cardiovasc Drugs Ther, 2009, 23: 49-59.
  • 4Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) bound to LDL and HDL. Curr Pharm Des, 2014, 20: 6256-6269.
  • 5Xu RX, Zhang Y, Li XL, et al. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease. Clin Cbim Aeta, 2015, 446: 195-200.
  • 6Yang M, Chu EM, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes. Biochim Biophys Acta, 2010, 1801: 176-182.
  • 7Silva IT, Mello AP, Damasceno NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids Health Dis, 2011, 10: 170.
  • 8Kolodgie F, Burke A, Skorija K, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atheroselerosis. Arterioscler Thromh Vasc Biol, 2006, 26: 2523-2529.
  • 9Fenning RS, Burgert ME, Hamamdzic D, et al. Atherosclerotic plaque inflammation varies between vascular sites and correlates with respons to inhibition of lipoprotein-associated phospholipase A2. J Am Heart Assoc, 2015, 4. pii: e001477, doi: 10. ll61/JAHA. 114. 001477.
  • 10Thompson A, Gao P, Orfei L, et al. Lip0protein-assoeiated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospeetive studies. Laneet, 2010, 375: 1536-1544.

共引文献1050

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部